{"id":4011,"date":"2026-09-05T17:33:44","date_gmt":"2026-09-05T14:33:44","guid":{"rendered":"https:\/\/wniss.com\/?p=4011"},"modified":"2026-09-05T17:34:44","modified_gmt":"2026-09-05T14:34:44","slug":"clinical-progress-advances-in-new-ssri-2022-research","status":"publish","type":"post","link":"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/","title":{"rendered":"Clinical Progress &#038; Advances in New SSRI 2022 Research"},"content":{"rendered":"\n<div class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\"><h1><span class=\"ez-toc-section\" id=\"Clinical_Progress_Advances_in_New_SSRI_2022_Research\"><\/span>Clinical Progress &amp; Advances in New SSRI 2022 Research<span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p>Research published during <strong>2022<\/strong> did not introduce an entirely new class of selective serotonin reuptake inhibitors (SSRIs). Instead, it significantly advanced understanding of how existing SSRIs work, why they benefit some patients more than others, and how future antidepressants may improve upon traditional SSRIs.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Clinical_Progress_Advances_in_New_SSRI_2022_Research\" >Clinical Progress &amp; Advances in New SSRI 2022 Research<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Major_Clinical_Advances_in_2022\" >Major Clinical Advances in 2022<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Better_Understanding_of_SSRI_Response\" >Better Understanding of SSRI Response<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Serotonin_Transporter_Occupancy\" >Serotonin Transporter Occupancy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Faster-Acting_Antidepressant_Strategies\" >Faster-Acting Antidepressant Strategies<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Expanding_Beyond_the_Traditional_SSRI_Model\" >Expanding Beyond the Traditional SSRI Model<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Precision_Psychiatry\" >Precision Psychiatry<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Cognitive_Symptoms_Receive_More_Attention\" >Cognitive Symptoms Receive More Attention<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Clinical_Implications\" >Clinical Implications<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/wniss.com\/en-gb\/clinical-progress-advances-in-new-ssri-2022-research\/#Overall_Significance\" >Overall Significance<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<h2><span class=\"ez-toc-section\" id=\"Major_Clinical_Advances_in_2022\"><\/span>Major Clinical Advances in 2022<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Better_Understanding_of_SSRI_Response\"><\/span>Better Understanding of SSRI Response<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>One of the most influential 2022 analyses examined more than 8,000 patients from FDA-registered clinical trials. Researchers found that SSRIs appear to improve <strong>depressed mood and psychic anxiety early<\/strong>, with later improvements in other symptoms occurring indirectly as mood improves. This challenged the idea that all depressive symptoms respond equally to SSRI treatment. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 73px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Serotonin_Transporter_Occupancy\"><\/span>Serotonin Transporter Occupancy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A comprehensive systematic review clarified the relationship between antidepressant dose and serotonin transporter (SERT) occupancy. Key findings included:<\/p>\n<ul>\n<li>\n<p>Most SSRIs achieve high SERT occupancy at standard therapeutic doses.<\/p>\n<\/li>\n<li>\n<p>Increasing the dose beyond moderate levels often provides limited additional transporter blockade.<\/p>\n<\/li>\n<li>\n<p>Clinical decisions should balance symptom improvement against the risk of dose-related adverse effects. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 101px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Faster-Acting_Antidepressant_Strategies\"><\/span>Faster-Acting Antidepressant Strategies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Although conventional SSRIs often require several weeks before full clinical benefit appears, researchers reported promising preclinical work targeting the interaction between:<\/p>\n<ul>\n<li>\n<p>Serotonin transporter (SERT)<\/p>\n<\/li>\n<li>\n<p>Neuronal nitric oxide synthase (nNOS)<\/p>\n<\/li>\n<\/ul>\n<p>Disrupting this interaction produced antidepressant-like effects within hours in animal models, suggesting a possible pathway for future rapid-onset medications. These compounds are <strong>not currently approved SSRIs<\/strong> but represent an important research direction. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 56px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Expanding_Beyond_the_Traditional_SSRI_Model\"><\/span>Expanding Beyond the Traditional SSRI Model<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>During 2022, several reviews emphasized that future antidepressants may move beyond simple serotonin reuptake inhibition by targeting multiple biological systems simultaneously, including:<\/p>\n<ul>\n<li>\n<p>Glutamate signaling<\/p>\n<\/li>\n<li>\n<p>Neuroplasticity<\/p>\n<\/li>\n<li>\n<p>Inflammation<\/p>\n<\/li>\n<li>\n<p>Neurosteroid pathways<\/p>\n<\/li>\n<li>\n<p>Stress-response mechanisms<\/p>\n<\/li>\n<\/ul>\n<p>This multitarget approach aims to improve efficacy while reducing delayed onset and treatment resistance. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 62px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">PubMed<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Precision_Psychiatry\"><\/span>Precision Psychiatry<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Researchers increasingly focused on identifying which patients are most likely to respond to SSRIs. Areas of investigation included:<\/p>\n<ul>\n<li>\n<p>Genetic biomarkers<\/p>\n<\/li>\n<li>\n<p>Brain imaging<\/p>\n<\/li>\n<li>\n<p>Cognitive profiles<\/p>\n<\/li>\n<li>\n<p>Digital phenotyping<\/p>\n<\/li>\n<li>\n<p>Machine learning prediction models<\/p>\n<\/li>\n<\/ul>\n<p>These advances support a future of personalized antidepressant prescribing rather than trial-and-error medication selection. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 71px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+1<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cognitive_Symptoms_Receive_More_Attention\"><\/span>Cognitive Symptoms Receive More Attention<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Traditional SSRI research primarily emphasized mood improvement. However, 2022 reviews highlighted persistent problems such as:<\/p>\n<ul>\n<li>\n<p>Poor concentration<\/p>\n<\/li>\n<li>\n<p>Memory impairment<\/p>\n<\/li>\n<li>\n<p>Executive dysfunction<\/p>\n<\/li>\n<\/ul>\n<p>Researchers concluded that cognitive symptoms remain an important unmet treatment need and may require therapies beyond standard SSRIs. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 56px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between overflow-hidden\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Clinical_Implications\"><\/span>Clinical Implications<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The evidence published in 2022 suggests that clinicians should:<\/p>\n<ul>\n<li>\n<p>Recognize that symptom improvement occurs in stages rather than simultaneously.<\/p>\n<\/li>\n<li>\n<p>Use therapeutic doses rather than assuming higher doses produce proportionally better results.<\/p>\n<\/li>\n<li>\n<p>Consider individualized treatment strategies based on patient characteristics.<\/p>\n<\/li>\n<li>\n<p>Combine medication with psychotherapy and lifestyle interventions when appropriate.<\/p>\n<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Overall_Significance\"><\/span>Overall Significance<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The major contribution of <strong>2022 SSRI research<\/strong> was not the approval of new SSRI drugs, but rather a deeper understanding of antidepressant mechanisms, dosing, symptom-specific responses, and future therapeutic targets. These findings are helping guide development of faster-acting and more personalized treatments for major depressive disorder and related conditions. <span class=\"\"><span class=\"ms-1 inline-flex max-w-full items-center select-none relative top-[-0.094rem] translate-y-0.5 animate-[show_150ms_ease-in]\" style=\"width: 71px;\"><span class=\"flex h-4.5 overflow-hidden rounded-xl pe-2 ps-1 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! select-none\"><span class=\"relative start-0 bottom-0 flex h-full w-full items-center\"><span class=\"flex h-4 w-full items-center justify-between\" style=\"opacity: 1; transform: none;\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+2<\/span><\/span><span class=\"flex h-4 w-full items-center justify-between absolute\" style=\"opacity: 0; transform: translateX(10%);\"><span class=\"flex min-w-0 flex-1 items-center gap-1\"><span class=\"inline-flex shrink-0 items-center justify-center overflow-hidden rounded-full\"><\/span><span class=\"max-w-[15ch] grow truncate overflow-hidden text-center\">Nature<\/span><\/span><span class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\">+2<\/span><\/span><\/span><\/span><\/span><\/span><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Progress &amp; Advances in New SSRI 2022 Research Research published during 2022 did not introduce an entirely new class of selective serotonin reuptake inhibitors (SSRIs). Instead, it significantly advanced understanding of how existing SSRIs work, why they benefit some patients more than others, and how future antidepressants may improve upon traditional SSRIs. Major Clinical&#8230;<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[730],"tags":[],"class_list":["post-4011","post","type-post","status-publish","format-standard","hentry","category-depression"],"acf":[],"_links":{"self":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/comments?post=4011"}],"version-history":[{"count":2,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4011\/revisions"}],"predecessor-version":[{"id":5768,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/posts\/4011\/revisions\/5768"}],"wp:attachment":[{"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/media?parent=4011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/categories?post=4011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wniss.com\/en-gb\/wp-json\/wp\/v2\/tags?post=4011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}